SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-021952
Filing Date
2024-05-09
Accepted
2024-05-09 07:07:02
Documents
84
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vnda-20240331.htm   iXBRL 10-Q 929853
2 EX-31.1 vndaex311331202410q.htm EX-31.1 10477
3 EX-31.2 vndaex312331202410q.htm EX-31.2 10101
4 EX-32.1 vndaex321331202410q.htm EX-32.1 6660
  Complete submission text file 0001628280-24-021952.txt   5735941

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20240331.xsd EX-101.SCH 49393
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20240331_cal.xml EX-101.CAL 64101
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20240331_def.xml EX-101.DEF 213772
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20240331_lab.xml EX-101.LAB 561505
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20240331_pre.xml EX-101.PRE 408268
88 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20240331_htm.xml XML 692552
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 24928514
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)